Carmell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Cash & Equivalents	2.91	0.13	0.01
Cash & Cash Equivalents	2.91	0.13	0.01
Cash Growth	2172.71%	936.64%	-
Other Current Assets	59.99	0.48	0.17
Total Current Assets	62.9	0.61	0.18
Property, Plant & Equipment	1.02	1.11	1.35
Goodwill and Intangibles	0.02	0.03	0.03
Total Long-Term Assets	1.05	1.14	1.38
Total Assets	63.95	1.75	1.56
Accounts Payable	4.42	2.14	0.87
Current Debt	1.44	2.91	8.72
Other Current Liabilities	32.65	2.25	6.21
Total Current Liabilities	38.5	7.3	15.8
Long-Term Debt	0.7	0.83	0.96
Other Long-Term Liabilities	0	0	0.03
Total Long-Term Liabilities	0.7	0.83	1
Total Liabilities	39.2	8.12	16.8
Total Debt	2.14	3.74	9.69
Debt Growth	-42.80%	-61.44%	-
Retained Earnings	-58.5	-42.38	-32.77
Shareholders' Equity	24.75	-37.79	-29.58
Net Cash / Debt	0.78	-3.61	-9.67
Net Cash Per Share	0.07	-2.05	-0.42
Working Capital	24.4	-6.69	-15.62
Book Value Per Share	2.25	-21.51	-1.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).